注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Poseida Therapeutics Inc是一家临床阶段的生物制药公司,利用其基因工程平台技术开发细胞和基因疗法。该公司的平台包括我们的非病毒piggyBac DNA递送系统、Cas-CLOVER位点特异性基因编辑系统以及基于纳米颗粒和AAV的基因递送技术。其正在开发的先进候选产品P-PSMA-101用于治疗转移性去势抵抗性前列腺癌(mCRPC)患者,处于I期试验。其前两个全同种异体CAR-T候选产品包括P-BCMA-ALLO1和P-MUC1C-ALLO1,均处于I期试验阶段。P-BCMA-ALLO1是为复发/难治性多发性骨髓瘤患者开发的。P-MUC1C-ALLO1正在被开发用于治疗一系列实体瘤,包括乳腺癌、卵巢癌和其他上皮源性癌症。此外,该公司还有几个额外的同种异体项目向预期的IND申请推进,包括P-CD19CD20-ALLO1。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Mark J. Gergen | 61 | 2018 | Executive Chairman of the Board |
Cynthia L. Collins | 66 | 2021 | Independent Director |
John P. Schmid | 61 | 2018 | Lead Independent Director |
Luca Gattinoni | - | 2021 | Member of Scientific Advisory Board |
Luke David Corning | 42 | 2020 | Independent Director |
Mark A. Kay | 65 | 2023 | Member of Gene Therapy Scientific Advisory Board |
Marcea Bland Lloyd | 75 | 2019 | Independent Director |
Carl H. June | 69 | 2021 | Chairman of Cell Therapy Scientific Advisory Board |
Jan Joseph Melenhorst | - | 2021 | Member of Scientific Advisory Board |
Christine Brown | - | 2021 | Member of Scientific Advisory Board |
Julian Grunewald | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Kathryn A. Whitehead | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Ian E. Alexander | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Charles M. Baum | 66 | 2022 | Independent Director |
Rafael G. Amado | 60 | 2023 | Director |
George McDonald Church | 70 | 2022 | Chairman of Gene Therapy Scientific Advisory Board |
Mark Tracy | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Kristin Yarema | 53 | 2023 | President, CEO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核